These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31749151)

  • 1. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
    Zinngrebe J; Schlichtig F; Kraus JM; Meyer M; Boldrin E; Kestler HA; Meyer LH; Fischer-Posovszky P; Debatin KM
    Int J Cancer; 2020 Jun; 146(11):3219-3231. PubMed ID: 31749151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
    Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
    Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
    Hannes S; Abhari BA; Fulda S
    Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
    Gerges S; Rohde K; Fulda S
    Cancer Lett; 2016 May; 375(1):127-132. PubMed ID: 26944210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.
    Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB
    Cancer Res; 2016 Aug; 76(15):4579-91. PubMed ID: 27302164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
    McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
    Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
    Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
    Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
    Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
    Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The IAP Protein Family, SMAC Mimetics and Cancer Treatment.
    Philchenkov A; Miura K
    Crit Rev Oncog; 2016; 21(3-4):185-202. PubMed ID: 27915971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly.
    Belz K; Schoeneberger H; Wehner S; Weigert A; Bönig H; Klingebiel T; Fichtner I; Fulda S
    Blood; 2014 Jul; 124(2):240-50. PubMed ID: 24855207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer.
    Zhang T; Li Y; Zou P; Yu JY; McEachern D; Wang S; Sun D
    Biopharm Drug Dispos; 2013 Sep; 34(6):348-59. PubMed ID: 23813446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis.
    Uzunparmak B; Gao M; Lindemann A; Erikson K; Wang L; Lin E; Frank SJ; Gleber-Netto FO; Zhao M; Skinner HD; Newton J; Sikora AG; Myers JN; Pickering CR
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33108350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of necroptosis by Smac mimetic bypasses apoptosis resistance in acute myeloid leukemia cells.
    Safferthal C; Rohde K; Fulda S
    Oncogene; 2017 Mar; 36(11):1487-1502. PubMed ID: 27869161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
    Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
    Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.